Advertisement


Krzysztof Bujko, MD, on Rectal Cancer: Results of a Phase III Trial

2016 Gastrointestinal Cancers Symposium

Advertisement

Krzysztof Bujko, MD, of the Maria Skłodowska Curie Memorial Cancer Centre, discusses the results of a multicenter Polish study on neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancer (Abstract 489).



Related Videos

Colorectal Cancer

Heinz-Josef Lenz, MD, on Metastatic Colorectal Cancer: Results of the MAVERICC Study (German Language Version)

Heinz-Josef Lenz, MD, of the USC Norris Comprehensive Cancer Center, discusses in German the findings of this phase II study of mFOLFOX6/bevacizumab vs FOLFIRI/bevacizumab with biomarker stratification in patients with metastatic colorectal cancer (Abstract 493).

Gastroesophageal Cancer

Toshihiko Doi, MD, PhD, on Esophageal Carcinoma: Study Results From KEYNOTE-028

Toshihiko Doi, MD, PhD, of Japan’s National Cancer Center Hospital East, discusses updated results on pembrolizumab for advanced esophageal cancer (Abstract 7).

Gastroesophageal Cancer

Simron Singh, MD, on Neuroendocrine Tumors of the GI Tract: Results from the RADIANT-4 Trial

Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors of the GI tract and unknown primary (Abstract 315).

Gastroesophageal Cancer

Somnath Mukherjee, MD, on Esophageal Adenocarcinoma: Results of the NEOSCOPE Trial

Somnath Mukherjee, MD, of Oxford University, discusses this phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine- or paclitaxel/carboplatin-based chemoradiation as a pre-operative regimen for resectable esophageal cancer.. (Abstract 3).

Gastroesophageal Cancer

Jonathan R. Strosberg, MD, on Neuroendocrine Tumors: Results of the NETTER-1 Trial

Jonathan R. Strosberg, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses progression-free survival, radiographic response, and preliminary overall survival findings of this phase III study on midgut neuroendocrine tumors treated with lutetium Lu-177 dotatate (Abstract 194).

Advertisement

Advertisement




Advertisement